ev3 — Investor Presentation (January 2010)
29 slides from ev3's investor presentation, Jan 12, 2010
Slide 1: ev3 Investor Presentation
ev3 Investor Presentation Robert Palmisano, President & CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "intend,
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation. ev3 uses non-GAAP financial measures as supplemental measures of performance and believes these measures provide useful information to investors in evaluating our operations, period over period. How
Slide 4: The ev3 Story
The ev3 Story Setting The global medical device market for peripheral vascular and neurovascular diseases is >$2.5B and growing The Company ev3 is a leading global medical device company focused on breakthrough endovascular treatments The Strategy Executing a focused plan to: grow at or above the ma
Slide 5: Gaining Market Share in Both Segments
Gaining Market Share in Both Segments 1 YTD Q3 2009 product revenues * 2010 - Internal estimates (PV market includes stents, atherectomy and PTA balloons only; NV market includes coils, flow diversion, liquid embolics, access devices and ischemic stroke therapy) Business WW Market Size/Growth Market
Slide 6: A Record of Setting and Meeting Goals
A Record of Setting and Meeting Goals Goal Result Status Grow at/above market rates Expand gross margins Achieve & sustain profitability Generate cash Integrate/stabilize FoxHollow acquisition Add breakthrough growth platforms * Q3'09 vs. Q3'08 Ongoing 1,000+ basis pt. improvement* Profitable from Q
Slide 7: Two Growth Platforms: Neurovascular Business
Two Growth Platforms Neurovascular Business 1 Peripheral Vascular Business 2
Slide 8: ev3 Neurovascular: Building a Global Leader
Strong sales growth record - 2X market ev3 Neurovascular: Building a Global Leader Competitive strengths #2 globally Strong international footprint Over 65 countries Constant product innovation ? leadership #1 in liquid embolics 8 new launches in 2009 Launching breakthrough products 2 new markets >
Slide 9: Future Growth Drivers
Future Growth Drivers Grow base business - next generation products AXIUM(tm) MicroFx (PGLA, Nylon) New Access Products Apollo(tm) Micro-Catheter for Onyx(r) Liquid Embolic Breakthrough products Pipeline(tm) ? $350M market potential Solitaire(tm) ? untapped ischemic stroke market Clinical trials 4 u
Slide 10: Pipeline Device - A True Breakthrough Product
A CLOSER LOOK Pipeline(tm) Device - A True Breakthrough Product Significant market opportunity $350M "large aneurysm" global market unmet need First mover advantage Compelling clinical data Launched in Europe, Int'l markets U.S. PMA approval anticipated 2011 Investigational Use Only in the United St
Slide 11: Significant Market Opportunity for Pipeline Solution
49%2 ev3 estimates; Worldwide aneurysm procedures suitable for endovascular treatment in 2013; excludes ruptured aneurysms Assumed treatable with flow diversion device (large & giant, wide-neck, or nonsaccular aneurysms) Significant Market Opportunity for Pipeline(tm) Solution Potential Endovascular
Slide 12: Pipeline Device - Offers Significant Advantages
A CLOSER LOOK Pipeline(tm) Device - Offers Significant Advantages Investigational Use Only in the United States: Not FDA approved or cleared Pipeline(tm) Device Treats giant aneurysms effectively YES Low recurrence YES Faster procedure time YES Treats root cause of aneurysms - parent artery YES
Slide 13: Pipeline Embolization Device: How It Works
PIPELINE(tm) EMBOLIZATION DEVICE (PED): How It Works Step 1: Insert guidewire and microcatheter Step 2: Deliver PIPELINE(tm) through microcatheter Step 3: Extract microcatheter and expand PIPELINE(tm) Step 4: Withdraw delivery wire Investigational Use Only in the United States: Not FDA approved or c
Slide 14: Pipeline Case Example: Standalone Treatment of Aneurysm
PIPELINE(tm) CASE EXAMPLE: Standalone Treatment of Aneurysm Investigational Use Only in the United States: Not FDA approved or cleared Before Post treatment 1 month follow up After No recurrence Treated with Pipeline(tm) Aneurysm
Slide 15: Solitaire FR: Breakthrough Product for Ischemic Stroke
A CLOSER LOOK Solitaire(tm) FR: Breakthrough Product for Ischemic Stroke Attractive market significant unmet clinical need U.S. stroke incidence 795,000 people annually; 87% are ischemic* Growing opportunity for endovascular device-based therapies Solitaire(tm) FR Revascularization Device unique des
Slide 16: Solitaire FR Case Example: Clot Removed in 15 Minutes
Initial angiogram of occlusion in left middle cerebral artery (taken at 8:53pm) After deploying Solitaire(tm) FR and retrieving the clot, flow is restored to the left middle cerebral artery (taken at 9:08pm) SOLITAIRE(tm) FR CASE EXAMPLE: Ischemic Clot Removed and Flow Restored - in 15 Minutes After
Slide 17: Two Growth Platforms: Peripheral Vascular Business
Two Growth Platforms Neurovascular business 1 Peripheral Vascular Business 2
Slide 18: ev3 Peripheral Vascular - Positioned for Growth
ev3 Peripheral Vascular - Positioned for Growth Competitive Strengths Only company that addresses all major PAD treatments Leader (#1 share) in plaque excision / atherectomy key point of differentiation Meaningful clinical / technology pipeline indications (SFA, iliac, calcium, carotid) platforms (p
Slide 19: Peripheral Vascular Sales Force Productivity in U.S.
Annualized Net Sales Per Territory Q3'09 up 29% vs. Q3'08 Key Drivers Plaque Excision Clinical Specialists GPO/IDN penetration Market development DEFINITIVE clinical data Neuro business already > $2M per territory Peripheral Vascular Sales Force Productivity in U.S. Continues to Improve Q3 08 Q1 09
Slide 20: Future Growth Drivers
Future Growth Drivers Grow base business Global PTA Balloon launch Expanded Plaque Excision tool kit TurboHawk(tm) above-the-knee TrailBlazer(tm) catheter New products TurboHawk below-the-knee 2H'10 EverFlex+ 4Q'10 Next Gen Plaque Excision 2H'11 Clinical studies 4 studies underway to drive growth an
Slide 21: Hawk is a Key Differentiator - Keeps Getting Better
A CLOSER LOOK Hawk is a Key Differentiator - Keeps Getting Better New TurboHawk(tm) - plaque excision above-the-knee cuts through difficult plaque and calcium faster easier for physicians to use Launched in U.S. for endovascular use incremental opportunity to treat mild to moderately calcified lesio
Slide 22: TurboHawk Case Example: Calcified SFA Occlusion
TurboHawk(tm) CASE EXAMPLE: Calcified SFA Occlusion Pre-TurboHawk(tm) Post-TurboHawk(tm) Calcified SFA occlusion Treated with TurboHawk(tm) Calcified debris removed from SFA
Slide 23: DEFINITIVE Trial Series: A Key Catalyst
A CLOSER LOOK AT DEFINITIVE TRIAL SERIES: A Key Catalyst to Accelerate Atherectomy Growth Broader usage by Peripheral Endovascular Specialists Core User Group: "Hawkers" Establish plaque excision as a front-line therapy 3 trials, enroll 600-900 patients TRIAL SERIES Clinical Data
Slide 24: ev3 International: Continued Sales Momentum
International Revenue* ev3 International: Continued Sales Momentum Competitive strengths Strong share & growth in EU Robust emerging market presence Brazil, China, Russia, India, Korea, Japan International product launches NV: Pipeline(tm), Solitaire(tm) PV: TurboHawk(tm), ev3-PTA balloons 06 07 08
Slide 25: International Markets will Fuel Growth and Expansion
Successful launch of Pipeline(tm), Solitaire(tm) Reimbursement for SilverHawk(r) International Markets will Fuel Growth and Expansion Across Both Businesses Market development (flow diversion, stroke, atherectomy) Grow neurovascular market share; develop peripheral vascular market Direct sales Gover
Slide 26: Financial Summary: Continuing to Improve Performance
FINANCIAL SUMMARY: Continuing to Improve Performance Net Product Sales* $100,018 $105,656 $100,395 $109,086 $112,838 Gross Profit $68,747 $71,316 $69,407 $78,608 $84,230 Gross Margin 64.2% 67.2% 69.1% 72.1% 74.6% Net Income (loss) $(7,310) $(291,120) $(1,809) $23,989 $6,736 Adjusted EPS per Diluted
Slide 27: Key Growth Drivers
Key Growth Drivers Long growth runway 3. Next gen plaque excision 1. Commercial execution 2. Flow diversion 5. International 6. Clinical studies 7. Selective M&A 4. Ischemic stroke
Slide 28: In Summary: Why Invest in ev3
IN SUMMARY: WHY INVEST IN ev3 ev3: Leading the Way Investing in 8 clinical studies to expand usage Powerful Growth Drivers Robust pipeline of novel products - 20 launches by 2012 Leveraging business model improving gross margin expanding operating income Pipeline(tm) - a game changing product Profit
Slide 29: Your endovascular company.”
Your endovascular company.”